Health
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
Four big drugmakers allegedly paid tens of millions of dollars to middlemen to supply lifesaving drugs to Russian government entities
- Published
- (1 h ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 20-word snippet. The full article is at the source.
More from STAT News and around the same time
STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countriesThe FDA has approved a generic HIV prevention shot, a key step in widening access for dozens of lower-income countries.A STAT reporter on covering MRT as an experimental fertility treatmentInside the global fertility industry using women as "guinea pigs":Are you pursuing MRT as a treatment for infertility?Are you pursuing MRT as a treatment for infertility? STAT wants to hear from youOpinion: Cancer patients are often pressured to end a pregnancy early. They shouldn’t beWomen can be safely treated for many cancers during pregnancy, a maternal fetal medicine specialist writes.Opinion: The economics of the U.S. health care system are broken“The economics of the U.S. health care system are broken,” writes Paul Markovich, president and CEO of Ascendiun.STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival DupixentInvestors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
